Abstract
[1] Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010;70:1600–7. [2] Sciarra A, Abrahamsson PA, Brausi M, et al. Intermittent androgendeprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722–30. [3] Isaacs JT, D’Antonio JM, Chen S, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate 2012;72:1491–505.